Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2019-03-08 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于公司高管辞职及新聘任高管的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company's financial director and the appointment of a new financial director. It includes details about the outgoing and incoming executives, their shareholdings, and compliance with relevant laws and regulations. There is no financial data, report, or presentation content. This fits the category of Board/Management Information, which covers announcements of changes in senior management.
2019-03-08 Chinese
独立董事的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion report related to various corporate governance matters including profit distribution, related party transactions, internal control evaluation, appointment of auditors, and appointment of a financial director. It references compliance with Chinese securities regulations and company bylaws. The document is about independent directors providing their opinions on board meeting resolutions and governance issues, not a full annual report or financial statements. It is not a short announcement but a detailed governance-related opinion document. This fits best under Board/Management Information (MANG) as it deals with board opinions and governance matters including appointment of a financial director and approval of related party transactions.
2019-03-08 Chinese
2018年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2018 年度内部控制评价报告' which translates to '2018 Annual Internal Control Evaluation Report'. It is a detailed report on the company's internal control evaluation, covering governance, organizational structure, financial reporting controls, risk management, and other internal control aspects. The document includes detailed descriptions of internal control policies, evaluation scope, defect recognition standards, and conclusions about the effectiveness of internal controls. It is not an announcement or a brief summary but a comprehensive report on internal control evaluation. This type of document fits the category of an Audit Report / Information (AR), which includes standalone audit reports and internal control evaluation results. The document is not an Annual Report (10-K) as it does not cover full financial performance or company activity broadly, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains substantive content and is not merely an announcement. Therefore, the correct classification is AR with high confidence. FY 2018
2019-03-08 Chinese
第七届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of 普洛药业股份有限公司 regarding the review and approval of the 2018 Annual Report, Supervisory Board Work Report, Financial Statements, Internal Control Evaluation Report, Profit Distribution Plan, and other related proposals. It includes voting results and mentions that these proposals will be submitted to the shareholders' meeting for approval. The document does not contain the full annual report or detailed financial statements but rather the Supervisory Board's review and approval of these reports and plans. This type of document is typically classified as a Regulatory Filing (RNS) because it is an official announcement of board resolutions and approvals related to the annual report and other corporate governance matters, not the annual report itself or a detailed financial report.
2019-03-08 Chinese
股东大会议事规则（2019年3月）
Governance Information Classification · 95% confidence The document is titled as "股东大会议事规则" which translates to "Rules of Procedure for the Shareholders' General Meeting." It details the procedures, powers, notification requirements, proposal handling, meeting registration, voting, and announcement rules related to shareholders' meetings. It does not contain any financial data, results, or reports but rather governance and procedural rules for conducting shareholder meetings. This fits the definition of Governance Information (CGR), which covers internal rules, board structure, and governance practices. The document length is 8043 characters, which is substantive and not a mere announcement or notice. Therefore, the appropriate classification is CGR with high confidence.
2019-03-08 Chinese
关于修改《公司章程》的议案
Governance Information Classification · 95% confidence The document is a detailed proposal for amendments to the company's Articles of Association (公司章程), including changes to governance, shareholding, board structure, and other corporate governance rules. It references compliance with company law, stock exchange listing rules, and regulatory guidelines. The content is focused on governance structure, shareholder rights, board and management roles, voting procedures, and related corporate governance matters. There is no indication that this is an annual report, financial statement, earnings release, or any other financial report. Instead, it is a governance-related document detailing internal rules and procedures of the company. Therefore, the document fits best under the category of Governance Information (CGR). The document length and detail also support that it is the actual governance document, not just an announcement or summary.
2019-03-08 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.